Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process.
Anion-exchange is the most popular chromatography technique in plasmid DNA purification. However, poor resolution of plasmid DNA from RNA often results in the addition of bovine-derived ribonuclease (RNase) A to degrade RNA impurities which raises regulatory concerns for the production of pharmaceutical-grade plasmid DNA. Low capacity for plasmid of most commercial media is another issue affecting the suitability of anion-exchange chromatography for large-scale processing. This study reports the use of anion-exchange chromatography to remove RNA in an RNase-free plasmid purification process. Resolution was achieved through careful selection of adsorbent and operating conditions as well as RNA reduction steps before chromatography. Dynamic capacity for plasmid was significantly increased (to 3.0mg/ml) so that it is now possible to envisage the large-scale manufacturing of therapeutic-grade plasmid DNA in the absence of added RNase using anion-exchange chromatography as a polishing step.
Eon-Duval
Alex
A
BioPharmaceutical Development, GlaxoSmithKline Research and Development Ltd., South Eden Park Road, Beckenham, Kent BR3 3BS, UK. aed98800@gsk.com
Burke
Gemma
G
D000837:Anion Exchange Resins; D002852:Chromatography, Ion Exchange / Q000379:methods*; D004247:DNA / Q000096:biosynthesis / Q000302:isolation & purification*; D004587:Electrophoresis, Agar Gel; D004926:Escherichia coli / Q000235:genetics; D010957:Plasmids / Q000302:isolation & purification*; D012260:Ribonucleases / Q000378:metabolism*
D000837:Anion Exchange Resins; D004247:DNA; D012260:Ribonucleases